Genor Biopharma Holdings Ltd. has announced its unaudited interim results for the six months ended 30 June 2025. The Group reported a total revenue of approximately RMB32.2 million for the Reporting Period, a significant increase compared to approximately RMB14.5 million for the same period in 2024. This growth in revenue was primarily driven by license and stock purchase agreements with TRC 2004, Inc. During the Reporting Period, the Group made substantial progress in strategic cooperation and the development and registration of drug candidate pipelines. Key achievements include the successful approval of the Class 1 innovative drug Lerociclib (Product name: Rujianing) by the NMPA on 27 May 2025. This drug is indicated for the treatment of adult patients. Furthermore, the Group has achieved a light-asset operation model, effectively reducing operating costs while actively promoting strategic cooperation. The Group has also submitted the New Listing Application for the Proposed Merger to the Stock Exchange, in line with its strategy to advance its pipeline developments.